Literature DB >> 23509363

Agonistic anti-CD40 induces thyrocyte proliferation and promotes thyroid autoimmunity by increasing CD40 expression on thyroid epithelial cells.

Timothy Kayes1, Yujiang Fang, Shiguang Yu, Edward Downey, Shufang Wang, Helen Braley-Mullen.   

Abstract

CD40 is expressed on cells of the immune system and in some tissues that are targets for autoimmune-mediated damage. It is not known if CD40 expression in target tissues plays a role in the pathology of autoimmune diseases. This study shows that agonistic anti-CD40 induces strong and sustained proliferation of thyroid epithelial cells (TECs), or thyrocytes, in IFN-γ(-/-) autoimmune-prone NOD and NOD.H-2h4 mice. TEC proliferation is accompanied by greatly increased expression of CD40 on TECs, development of fibrosis and hypothyroidism, and increased expression of proinflammatory molecules in thyroids. Bone marrow chimera experiments indicate that TEC expression of CD40 is required for anti-CD40-induced TEC proliferation, but lymphoid cells do not have to express CD40. TEC proliferation is reduced in wild-type mice given anti-CD40, presumably because they produce IFN-γ, which inhibits TEC proliferation. CD40 also increases on TECs during development of an autoimmune thyroid disease characterized by TEC hyperproliferation that develops spontaneously in IFN-γ(-/-) NOD.H-2h4 mice. TEC hyperproliferation development is accelerated in mice given agonistic anti-CD40. These studies provide new information regarding the role of target tissue expression of CD40 in development of autoimmunity and suggest that use of agonistic anti-CD40 for tumor therapy could result in autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23509363      PMCID: PMC3622184          DOI: 10.4049/jimmunol.1202929

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  CD40 on NOD CD4 T cells contributes to their activation and pathogenicity.

Authors:  Rocky L Baker; David H Wagner; Kathryn Haskins
Journal:  J Autoimmun       Date:  2008-10-31       Impact factor: 7.094

3.  Cytokines, thyroid autoantibody synthesis and thyroid cell survival in culture.

Authors:  S M McLachlan; J Taverne; M C Atherton; A Cooke; S Middleton; C A Pegg; F Clark; B Rees Smith
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

4.  Detection of CD40 on human thyroid follicular cells: analysis of expression and function.

Authors:  R A Metcalfe; R S McIntosh; F Marelli-Berg; G Lombardi; R Lechler; A P Weetman
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

5.  Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.

Authors:  Holm H Uhlig; Brent S McKenzie; Sophie Hue; Claire Thompson; Barbara Joyce-Shaikh; Renata Stepankova; Nicolas Robinson; Sofia Buonocore; Helena Tlaskalova-Hogenova; Daniel J Cua; Fiona Powrie
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

6.  Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice.

Authors:  D J Powell; J P Russell; G Li; B A Kuo; V Fidanza; K Huebner; J L Rothstein
Journal:  Oncogene       Date:  2001-05-31       Impact factor: 9.867

7.  Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice.

Authors:  Yoshihiro Inoue; Tomonori Kaifu; Akiko Sugahara-Tobinai; Akira Nakamura; Jun-Ichi Miyazaki; Toshiyuki Takai
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

8.  Anti-CD40 agonist antibodies: preclinical and clinical experience.

Authors:  Magi Khalil; Robert H Vonderheide
Journal:  Update Cancer Ther       Date:  2007-06-01

9.  TGF-beta promotes thyroid epithelial cell hyperplasia and fibrosis in IFN-gamma-deficient NOD.H-2h4 mice.

Authors:  Shiguang Yu; Gordon C Sharp; Helen Braley-Mullen
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

10.  Antitumor actions of interferon-gamma and interleukin-1 beta on human papillary thyroid carcinoma cell lines.

Authors:  I Yip; X P Pang; L Berg; J M Hershman
Journal:  J Clin Endocrinol Metab       Date:  1995-05       Impact factor: 5.958

View more
  5 in total

1.  New Murine Model of Early Onset Autoimmune Thyroid Disease/Hypothyroidism and Autoimmune Exocrinopathy of the Salivary Gland.

Authors:  Timothy Daniel Kayes; Gary A Weisman; Jean M Camden; Lucas T Woods; Cole Bredehoeft; Edward F Downey; James Cole; Helen Braley-Mullen
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

2.  Agonistic anti-CD40 promotes early development and increases the incidence of severe thyroid epithelial cell hyperplasia (TEC H/P) in CD4-/- mice.

Authors:  Shiguang Yu; Edward F Downey; Helen Braley-Mullen
Journal:  Immun Inflamm Dis       Date:  2013-10-30

3.  Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy.

Authors:  Kristin L Griffiths; Mushtaq Ahmed; Shibali Das; Radha Gopal; William Horne; Terry D Connell; Kelly D Moynihan; Jay K Kolls; Darrell J Irvine; Maxim N Artyomov; Javier Rangel-Moreno; Shabaana A Khader
Journal:  Nat Commun       Date:  2016-12-22       Impact factor: 14.919

4.  Compelling Evidence Linking CD40 Gene With Graves' Disease in the Chinese Han Population.

Authors:  He Jiang; Fei-Fei Yuan; Hai-Ning Wang; Wei Liu; Xiao-Ping Ye; Shao-Ying Yang; Hui-Jun Xie; Sha-Sha Yu; Yu-Ru Ma; Le-Le Zhang; Shuang-Xia Zhao; Huai-Dong Song
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-18       Impact factor: 5.555

Review 5.  The Role of the Transcription Factor Nuclear Factor-kappa B in Thyroid Autoimmunity and Cancer.

Authors:  Cesidio Giuliani; Ines Bucci; Giorgio Napolitano
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-21       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.